Мона Александровна Фролова
Russian Cancer Research Center NN Blokhin · 92 works · 226 citations · h-index 9
Top works
- Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
- Randomized, Double-Blind Study Comparing Proposed Biosimilar La-Ep2006 with Reference Pegfilgrastim in Breast Cancer
- Практические рекомендации по лекарственному лечению рака молочной железы
- Practical tools to facilitate the choice of adjuvant systemic therapy for resectable luminal HER2‑negative breast cancer
- Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients.
- The first BGICC consensus and recommendations for breast cancer awareness, early detection and risk reduction in low‐ and middle‐income countries and the MENA region
- Olanzapine (OLN) versus aprepitant (APR) in patients receiving high-emetogenic chemotherapy: Final results of randomized phase II trial.
- Breast cancer
- EVALUATION OF EFFICACY AND TOXICITY OF NEOADJUVANT CHEMOTHERAPY WITH DOSE-DENSE DOXORUBICIN, CISPLATIN, AND PACLITAXEL IN PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
- Atherosclerosis of brachiocephalic arteries and arterial stiffness in patients with breast cancer
- Analysis of Circulating Tumor Cells in Patients with Triple Negative Breast Cancer during Preoperative Chemotherapy
- Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer
- CHANGES IN NEO- AND ADJUVANT TREATMENT OF BREAST CANCER IN THE LAST 5 YEARS
- EVALUATION OF EFFICACY AND TOXICITY OF NEOADJUVANT ALTERNATING CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER
- The role of the neoadjuvant approach in the treatment of primary operable HER2 positive breast cancer
- Palbociclib in the first line combination hormone therapy of HER2- negative metastatic hormone-dependent breast cancer. Clinical follow-up
- Primary systemic therapy with metronomic doxorubicin, cyclophosphamide, and capecitabine in locally advanced and metastatic triple-negative breast cancer.
- Neoadjuvant chemotherapy with metronomic doxorubicin, cyclophosphamide, and capecitabine in patients with locally advanced (LA) triple-negative breast cancer (TNBC).
- Efficacy and safety of intensified platinum-based neoadjuvant chemotherapy in locally advanced triple-negative breast cancer: Preliminary results of non-randomized phase II study.
- Effectiveness of risk-guided cardiac management in patients with HER2-positive breast cancer and cancer therapy-related cardiac dysfunction